

September 24, 2018

(b) (4), (b) (6) and/or (b) (4), (b) (6)
Advanced Bioscience Resources, Inc.
1516 Oak Street, Suite 303
Alameda, CA 94501-2958

Re: Purchase Order No. HHSF223201810184P; Termination for the Government's Convenience

Dear (b) (4), (b) (6) and (b) (4), (b) (6)

This letter is to inform you that the Government is terminating the above referenced purchase order for tissue to humanize the immune systems of mice (the "Purchase Order").

Based on the terms and conditions of the Purchase Order as awarded to Advanced Bioscience Resources, Inc. ("ABR") on July 27, 2018, the Government is not sufficiently assured that the human tissue provided to the Government to humanize the immune systems of mice will comply with the prohibitions set forth under 42 U.S.C. § 289g-2. Furthermore, the Government has concerns with the sufficiency of the sole-source justification. Therefore, pursuant to FAR clause 52.213-4(f), the Purchase Order is being terminated effective September 24, 2018.

FAR clause 52.213-4(f) provides, in part (emphasis added),

The Government reserves the right to terminate this contract, or any part hereof, for its sole convenience. In the event of such termination, **the Contractor shall immediately stop all work hereunder and shall immediately cause any and all of its suppliers and subcontractors to cease work.** Subject to the terms of this contract, the Contractor shall be paid a percentage of the contract price reflecting the percentage of the work performed prior to the notice of termination, plus reasonable charges that the Contractor can demonstrate to the satisfaction of the Government, using its standard record keeping system, have resulted from the termination.

We caution ABR that in accordance with FAR clause 52.213.4(f), you will not receive payment for "any work performed or costs incurred that reasonably could have been avoided."

We appreciate your cooperation and prompt attention to this matter. If you have any questions regarding this notice, please contact me at (b) (6)

Sincerely,

(b) (6)

Office of Operations, Office of Finance Budget & Acquisitions
Office of Acquisitions and Grants Services, HFT-320
U.S. Food and Drug Administration

TRANSMISSION VERIFICATION REPORT

TIME : 09/24/2018 15:09
NAME : U.S. FDA/NCTR
FAX : 8705437990
TEL :
SER.# : BROF0J174252

DATE, TIME
FAX NO./NAME
DURATION
PAGE(S)
RESULT
MODE

09/24 15:09
85108654090
00:00:19
01
OK
STANDARD
ECM

September 24, 2018

(b) (4), (b) (6) and/or (b) (4), (b) (6)

Advanced Bioscience Resources, Inc.
1516 Oak Street, Suite 303
Alameda, CA 94501-2958

Re: Purchase Order No. HHSF223201810184P; Termination for the Government's Convenience

Dear (b) (4), (b) (6) and (b) (4), (b) (6)

This letter is to inform you that the Government is terminating the above referenced purchase order for tissue to humanize the immune systems of mice (the "Purchase Order").

Based on the terms and conditions of the Purchase Order as awarded to Advanced Bioscience Resources, Inc. ("ABR") on July 27, 2018, the Government is not sufficiently assured that the human tissue provided to the Government to humanize the immune systems of mice will comply with the prohibitions set forth under 42 U.S.C. § 289g-2. Furthermore, the Government has concerns with the sufficiency of the sole-source justification. Therefore, pursuant to FAR clause 52.213-4(f), the Purchase Order is being terminated effective September 24, 2018.

FAR clause 52.213-4(f) provides, in part (emphasis added),

The Government reserves the right to terminate this contract, or any part hereof, for its sole convenience. In the event of such termination, the Contractor shall immediately stop all work hereunder and shall immediately cause any and all of its suppliers and subcontractors to cease work. Subject to the terms of this contract, the Contractor shall be paid a percentage of the contract price reflecting the percentage of the work performed prior to the notice of termination, plus reasonable charges that the Contractor can demonstrate to the satisfaction of the Government, using its standard record keeping system, have resulted from the termination.

We caution ABR that in accordance with FAR clause 52.213.4(f), you will not receive payment for "any work performed or costs incurred that reasonably could have been avoided." FDA2018-8273-000030

From: (b) (4), (b) (6)
To: (b) (6)
Subject: Re: HHSF223201810184P
Date: Wednesday, October 03, 2018 4:34:21 PM

Hello (b) (6),

There are no open invoices on P.O. #HHSF-223201810184P, which was terminated as of 24SEP2018 via an email on that date from:

(b) (6)
Acting Director, Division of Acquisition Programs
Office of Operations, Office of Finance Budget & Acquisitions
Office of Acquisitions and Grants Services, HFT-320
U.S. Food and Drug Administration

Thank you for checking.

(b) (4), (b) (6)



1516 Oak Street, #303
Alameda, CA 94501 U.S.A.
Phn: (b) (4), (b) (6)
Fax: 510-865-4090
Email: (b) (4), (b) (6)@abr-inc.com

On Tue, Oct 2, 2018 at 12:25 PM, (b) (6) <(b) (6)@fda.hhs.gov> wrote:

Hi (b) (4), (b) (6),

Can you verify there are no outstanding mice orders prior to 09/24/2018 and that all invoices have been paid?

Thank You

(b) (6)

Contract Specialist

Office of Operations, Office of Finance Budget & Acquisitions
Office of Acquisitions and Grants Services
U.S. Food and Drug Administration